Has Sejal Mehta received payments from drug or device companies?

Yes. Drug and device makers reported $3,689 in general payments to Sejal Mehta across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sejal Mehta did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sejal Mehta come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sejal Mehta

Psychiatry · Plano, TXNPI 1982612040

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,430 of the $3,689 with a category attached, or 65.9%. Johnson & Johnson accounts for 80.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $2,370 and has fallen 98.5% since, to $36 in 2025.

$3,689in general payments, 2019–2025

Across 45 payments — averaging $81.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$3K
Supernus Pharmaceuticals, Inc.$252
AbbVie$143
Teva Pharmaceuticals USA, Inc.$79
Sunovion Pharmaceuticals Inc.$77
Otsuka America Pharmaceutical, Inc.$64
plus $102 from 5 others

$3,332,400in research payments, 2019–2025

Across 469 payments — averaging $7105.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1.8M
Otsuka Pharmaceutical Development & Commercialization, Inc.$466K
Corium, LLC$327K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$213K
Bioxcel Therapeutics, Inc.$119K
Pfizer$97K
plus $319K from 9 others

What the payments were for

Consulting fees$2,43066%
Travel & lodging$662%
Food & beverage$1,19332%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	16	$2,972
Supernus Pharmaceuticals, Inc.	2	$252
AbbVie(2 entities)	8	$143
Teva Pharmaceuticals USA, Inc.	5	$79
Sunovion Pharmaceuticals Inc.	5	$77
Otsuka America Pharmaceutical, Inc.	3	$64
Indivior Inc.	2	$38
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	1	$20
Corium, LLC	1	$18
E.r. Squibb & Sons, L.L.C.	1	$14
Neuronetics, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,689 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Other psychiatry in Plano

Suresh SureddiPlano$2.2M
David CrumpackerPlano$386K
Rakesh JainLake Jackson$7.2M
Arvinder Pal WaliaAustin$2.5M
Martin GuerreroEl Paso$2M
Marty BennettAddison$1.8M
Matthew BramsHouston$1.5M
Vikram MehraKaty$1.2M
Joel HolinerDallas$948K
Frank ChenHouston$941K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →